Al's Comment:

 I love to see research on low grade gliomas.These tumors are usually ignored and excluded from most brain tumor trials. Although they do not discuss the numbers, it is great to see they met the endpoints.  

---

Posted on: 03/15/2023

Servier's Pivotal Phase 3 INDIGO Trial Investigating vorasidenib in IDH-Mutant Low-Grade Glioma Meets Primary Endpoint of Progression-Free Survival (PFS) and Key Secondary Endpoint of Time to Next Intervention (TTNI)

 

---

Click HERE to return to brain tumor news headlines.